Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 10487078 | Secreted proteins | August 2004 | May 2005 | Abandon | 32 | 0 | 0 | No | No |
| 10430633 | Human lysophosphatidic acid acyltransferase | May 2003 | February 2005 | Abandon | 22 | 1 | 1 | No | No |
| 10275546 | Novel serine-threonine kinase-4 | November 2002 | September 2004 | Abandon | 22 | 2 | 1 | No | No |
| 10149240 | Short peptides from the b4 and b5 regions kinases which selectively modulate protein activity | October 2002 | November 2004 | Abandon | 30 | 0 | 1 | No | No |
| 10235148 | Zcys5: a member of the cystatin superfamily | September 2002 | May 2004 | Abandon | 20 | 1 | 1 | No | No |
| 10130323 | HUMAN P21-ACTIVATED KINASE 5 POLYPEPTIDE | September 2002 | May 2005 | Allow | 37 | 1 | 1 | No | No |
| 10212877 | ISOLATED HUMAN PROTEASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND USES THEREOF | August 2002 | June 2004 | Allow | 23 | 0 | 1 | No | No |
| 10213439 | Conus gamma-carboxylase | August 2002 | June 2004 | Abandon | 22 | 0 | 1 | No | No |
| 10191807 | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | July 2002 | March 2005 | Abandon | 32 | 2 | 1 | No | Yes |
| 10177079 | Beta-1,3-galactosyltransferase homologs | June 2002 | March 2004 | Abandon | 20 | 0 | 1 | No | No |
| 10168582 | Human kinases | June 2002 | February 2005 | Abandon | 32 | 3 | 0 | No | No |
| 10174410 | Crystals and structures of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase MECPS | June 2002 | September 2004 | Abandon | 27 | 0 | 0 | No | No |
| 10162706 | Regulation of human serine/threonine protein kinase | June 2002 | July 2004 | Abandon | 25 | 2 | 1 | No | No |
| 10162435 | Novel human membrane-associated protein and cell surface protein family members | June 2002 | May 2005 | Abandon | 36 | 2 | 1 | No | No |
| 10159924 | Human beta-alanine-pyruvate aminotransferase | May 2002 | May 2004 | Abandon | 24 | 0 | 1 | No | No |
| 10160362 | NEMATODE ATP SYNTHASE SUBUNIT E-LIKE SEQUENCES | May 2002 | December 2004 | Allow | 31 | 2 | 0 | No | Yes |
| 10152874 | FARS1, a human secreted protein and uses thereof | May 2002 | May 2004 | Abandon | 23 | 1 | 1 | No | No |
| 09979624 | Crystal structure data of cysteinprotease gingipain r | May 2002 | May 2005 | Abandon | 42 | 0 | 1 | No | No |
| 09937243 | SYNTHESIS OF 1,2,3,4-TETRAHYDROXYBENZENES AND 1,2,3-TRIHYDROXYBENZENES USING MYO-INOSITOL-1-PHOSPHATE SYNTHASE AND MYO-INOSITOL 2-DEHYDROGENASE | May 2002 | January 2004 | Allow | 28 | 2 | 1 | No | No |
| 10136517 | Mammalian CDP-diacylglycerol synthase | May 2002 | April 2005 | Abandon | 35 | 1 | 1 | No | No |
| 10132585 | 26030, a human rho-GAP family member and uses therefor | April 2002 | March 2004 | Abandon | 22 | 0 | 1 | No | No |
| 10122067 | 27091, a phospholipid transporting ATPase molecule and uses therefor | April 2002 | January 2004 | Abandon | 21 | 0 | 1 | No | No |
| 10089644 | Molecules for disease detection and treatment | March 2002 | December 2004 | Abandon | 33 | 1 | 1 | No | No |
| 10103546 | Novel human kinases and polynucleotides encoding the same | March 2002 | February 2005 | Abandon | 35 | 2 | 0 | No | Yes |
| 10101235 | Phosphoinositide 3-kinase mediated inhibition of GPCRs | March 2002 | February 2005 | Abandon | 35 | 1 | 1 | No | No |
| 10090002 | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | March 2002 | June 2004 | Abandon | 27 | 1 | 1 | No | No |
| 10090695 | KITS FOR SCREENING FOR MODULATORS OF THE MOTOR PROTEIN HSKIP3B | March 2002 | August 2003 | Allow | 17 | 1 | 0 | No | No |
| 10090516 | Novel human TEN-M4/cdz proteins and polynucleotides encoding the same | March 2002 | February 2005 | Abandon | 36 | 2 | 0 | No | Yes |
| 10079709 | Cloning and expression of microbial phytase | February 2002 | May 2005 | Abandon | 38 | 1 | 1 | No | No |
| 10076157 | Phosphoriboxyl-pyrophosphate synthetase polypeptide | February 2002 | November 2004 | Allow | 33 | 1 | 1 | No | No |
| 10071223 | CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL CYCLASE | February 2002 | April 2004 | Allow | 27 | 0 | 0 | No | No |
| 10072130 | PROTEIN PHOSPHATASE ANTIBODIES | February 2002 | April 2005 | Abandon | 38 | 4 | 1 | No | Yes |
| 10060255 | 25 human secreted proteins | February 2002 | January 2005 | Abandon | 36 | 1 | 1 | No | No |
| 10059266 | Soluble chimeric G protein alpha subunits | January 2002 | May 2005 | Abandon | 39 | 0 | 1 | No | No |
| 10047991 | Purification of functional ribonucleoprotein complexes | January 2002 | April 2005 | Abandon | 39 | 0 | 1 | No | No |
| 10044303 | Protein expression and structure solution using specific fusion vectors | January 2002 | August 2004 | Abandon | 31 | 2 | 1 | No | No |
| 10023224 | Protein-protein interactions | December 2001 | May 2004 | Abandon | 29 | 0 | 1 | No | No |
| 10029653 | Enchanced PKR expression and cytokine production | December 2001 | May 2005 | Abandon | 41 | 1 | 1 | No | No |
| 10024036 | 68730 and 69112, protein kinase molecules and uses therefor | December 2001 | June 2004 | Abandon | 29 | 1 | 1 | No | No |
| 09980945 | Novel fabh enzyme, compositions capable of binding to said enzyme and methods of use thereof | December 2001 | August 2004 | Abandon | 32 | 1 | 1 | No | No |
| 10006467 | Zcys5: a member of the cystatin superfamily | December 2001 | September 2003 | Abandon | 21 | 1 | 1 | No | No |
| 09997664 | Method for the production of p-hydroxybenzoate in species of pseudomonas and agrobacterium | November 2001 | June 2005 | Abandon | 42 | 2 | 1 | No | No |
| 09937296 | ASSAYS FOR NUCLEOSIDE DIPHOSPHATES AND TRIPHOSPATES | November 2001 | November 2003 | Allow | 26 | 2 | 1 | No | No |
| 09993245 | Structures and methods for designing topoisomerase I inhibitors | November 2001 | June 2005 | Abandon | 43 | 1 | 1 | No | No |
| 09683025 | SELF-REGULATING VOLTAGE DIVIDER FOR SERIES-STACKED VOLTAGE RAILS | November 2001 | September 2002 | Allow | 10 | 0 | 0 | No | No |
| 10038288 | Novel human secreted proteins and polynucleotides encoding the same | November 2001 | September 2004 | Abandon | 34 | 2 | 1 | No | No |
| 10009219 | Methods using of fab I and compounds modulating fab I activity | November 2001 | September 2004 | Abandon | 34 | 1 | 1 | No | No |
| 10046583 | Methods and compositions for the identification of modulators of deoxyxylulose 5-phosphate synthase activity | October 2001 | December 2003 | Abandon | 26 | 1 | 0 | No | No |
| 10042930 | Novel enzymes which dehydrate glycerol | October 2001 | June 2005 | Abandon | 44 | 3 | 0 | No | No |
| 09744794 | Phosphorylation effectors | October 2001 | December 2004 | Abandon | 46 | 2 | 1 | No | No |
| 09970989 | MAMMALIAN LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE | October 2001 | June 2003 | Allow | 20 | 1 | 1 | No | No |
| 09970515 | CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY | October 2001 | April 2004 | Allow | 31 | 1 | 1 | No | No |
| 09965522 | Novel human sodium-dependent phosphate cotransporter | September 2001 | November 2004 | Abandon | 37 | 3 | 1 | No | No |
| 09962740 | POLYNUCLEOTIDE ENCODING A HUMAN PROTEASEINHIBITOR | September 2001 | October 2004 | Abandon | 37 | 2 | 1 | No | No |
| 09963159 | 3700, a novel human protein kinase and uses therefor | September 2001 | January 2004 | Abandon | 28 | 1 | 1 | No | No |
| 09960472 | Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae | September 2001 | December 2004 | Abandon | 39 | 2 | 0 | No | No |
| 09953259 | Nucleotide sequences coding for the ATR61protein | September 2001 | March 2004 | Abandon | 30 | 0 | 1 | No | No |
| 09951535 | Nucleotide sequences coding for the thrE gene and process for the enzymatic production of L-threonine using coryneform bacteria | September 2001 | June 2003 | Abandon | 21 | 1 | 0 | No | No |
| 09951536 | New nucleotide sequences coding for the thrE gene and process for the enzymatic production of L-threonine using coryneform bacteria | September 2001 | March 2003 | Abandon | 18 | 1 | 0 | No | No |
| 09950491 | 38646, a novel guanine nucleotide exchange factor and uses therefor | September 2001 | September 2004 | Abandon | 37 | 1 | 1 | No | No |
| 09945249 | CANDIDA GERANYLGERANYL- PROTEIN TRANSFERASE POLYPEPTIDE COMPOSITIONS AND METHODS RELATED THERETO | August 2001 | September 2003 | Allow | 32 | 2 | 1 | No | No |
| 09927597 | HUMAN SMOOTH MUSCLE MYOSIN HEAVY CHAIN | August 2001 | September 2004 | Allow | 37 | 2 | 1 | No | No |
| 09922185 | Catalases | August 2001 | August 2004 | Abandon | 36 | 0 | 1 | No | No |
| 09922199 | 15368, a novel human GTP-releasing factor family member and uses therefor | August 2001 | February 2004 | Abandon | 31 | 0 | 1 | No | No |
| 09917331 | Structure of beta-ketoacyl-[acyl carrier protein] synthases complexed with inhibitors and methods of use thereof | July 2001 | March 2005 | Abandon | 44 | 0 | 1 | No | No |
| 09700993 | ENDO-BETA-N-ACETYLGLUCOSAMINIDASE GENE | July 2001 | January 2004 | Allow | 38 | 2 | 1 | No | No |
| 09907495 | 32529, a novel human guanine nucleotide exchange factor family member and uses thereof | July 2001 | September 2003 | Abandon | 26 | 1 | 1 | No | No |
| 09901151 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | July 2001 | April 2003 | Allow | 21 | 1 | 1 | No | No |
| 09901884 | F0F1-ATPase and DNA encoding the same | July 2001 | May 2004 | Abandon | 34 | 2 | 1 | No | No |
| 09891865 | VECTORS, HOST CELLS, AND METHODS FOR PRODUCTION OF URIDINE PHOSPHORYLASE AND PURINE NUCLEOSIDE PHOSPHORYLASE | June 2001 | December 2004 | Allow | 42 | 2 | 1 | Yes | No |
| 09879389 | Aspartic acid proteases and nucleic acids encoding same | June 2001 | July 2003 | Abandon | 25 | 0 | 1 | No | No |
| 09870162 | THAUERA AROMATIC PHENYLPHOSPHATE CARBOXYLASE AND PHENYLPHOSPHATE SYNTHASE POLYPEPTIDES | May 2001 | December 2003 | Abandon | 30 | 3 | 0 | No | No |
| 09866108 | POLYNUCLEOTIDE ENCODING A HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND MUSCLE | May 2001 | September 2003 | Allow | 27 | 2 | 1 | No | No |
| 09862660 | LACTOBACILLUS BETA-GLUCURONIDASE AND DNA ENCODING THE SAME | May 2001 | August 2003 | Allow | 27 | 1 | 1 | No | No |
| 09855750 | THE FADD15 GENE OF CORYNEBACTERIUM GLUTAMICUM, ENCODING AN ACYL-COA SYNTHASE POLYPEPTIDE | May 2001 | May 2005 | Allow | 48 | 4 | 1 | Yes | No |
| 09854875 | 2786, a novel human aminopeptidase | May 2001 | June 2003 | Abandon | 26 | 1 | 1 | No | No |
| 09831455 | Human hydrolase proteins | May 2001 | March 2005 | Abandon | 46 | 2 | 1 | No | Yes |
| 09674501 | Methods of modifying the production of isopentenyl pyrophosphate, dimethylallyl pyrophosphate and/or isoprenoids | April 2001 | March 2004 | Abandon | 40 | 3 | 1 | No | No |
| 09839935 | Mouse histamine H3 gene | April 2001 | May 2003 | Abandon | 25 | 0 | 1 | No | No |
| 09836499 | 16051a and 16051b, novel human PDZ family members and uses thereof | April 2001 | July 2003 | Abandon | 27 | 1 | 1 | No | No |
| 09822862 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | April 2001 | June 2002 | Allow | 14 | 0 | 1 | No | No |
| 09816079 | Process for the fermentative preparation of L-amino acids using coryneform bacteria | March 2001 | September 2003 | Abandon | 30 | 1 | 1 | No | No |
| 09816860 | POLYNUCLEOTIDES ENCODING HUMAN GTPase ACTIVATING PROTEIN-4 POLYPEPTIDES | March 2001 | September 2003 | Abandon | 30 | 2 | 1 | No | No |
| 09813133 | ISOLATED HUMAN PROTEASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND USES THEREOF | March 2001 | May 2002 | Allow | 14 | 0 | 1 | No | No |
| 09810347 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | March 2001 | May 2002 | Allow | 14 | 0 | 1 | No | No |
| 09803472 | Novel estrogen-regulated G protein gamma subunit: compositions and methods of use | March 2001 | July 2004 | Abandon | 40 | 1 | 1 | No | No |
| 09786498 | Production of human erythropoietin | March 2001 | July 2003 | Abandon | 28 | 1 | 0 | No | No |
| 09797500 | Method of identifying inhibitors of CDC25 | March 2001 | June 2004 | Abandon | 40 | 0 | 1 | No | No |
| 09796100 | 40322, a novel human dynamin | February 2001 | August 2003 | Abandon | 29 | 2 | 1 | No | No |
| 09794257 | 32705, 23224, 27423, 32700, 32712, novel human G-proteins | February 2001 | November 2003 | Abandon | 33 | 1 | 1 | No | No |
| 09783388 | New nucleotide sequences coding for the thrE gene and process for the enzymatic production of L-threonine using coryneform bacteria | February 2001 | June 2003 | Abandon | 27 | 1 | 1 | No | No |
| 09781417 | 25 human secreted proteins | February 2001 | August 2002 | Abandon | 18 | 0 | 1 | No | No |
| 09769952 | Novel human enzymes and polynucleotides encoding the same | January 2001 | November 2004 | Abandon | 45 | 2 | 0 | No | Yes |
| 09765873 | POLYNUCLEOTIDE ENCODING A MUTANT RHODOTORULA GLUTINIS TYROSINE AMMONIA LYASE POLYPEPTIDE | January 2001 | September 2002 | Allow | 20 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEADMAN, DAVID J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STEADMAN, DAVID J works in Art Unit 1652 and has examined 94 patent applications in our dataset. With an allowance rate of 24.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner STEADMAN, DAVID J's allowance rate of 24.5% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STEADMAN, DAVID J receive 1.16 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by STEADMAN, DAVID J is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +77.2% benefit to allowance rate for applications examined by STEADMAN, DAVID J. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 61.5% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 63.2% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.7% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.